Moderna, inc. (MRNA)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16
Revenue:
Total revenue

60,209

135,068

205,825

108,396

Operating expenses:
Research and development

496,309

454,082

410,459

274,717

General and administrative

109,620

94,252

64,722

57,450

Total operating expenses

605,929

548,334

475,181

332,167

Loss from operations

-545,720

-413,266

-269,356

-223,771

Interest income

38,530

27,023

15,235

11,312

Other expense, net

-7,526

1,835

-1,875

-2,709

Loss before income taxes

-514,716

-384,408

-255,996

-215,168

Provision for (benefit from) income taxes

-695

326

-80

1,043

Net Income (Loss) Attributable to Parent

-514,000

-384,700

-255,900

-216,211

Net Income (Loss) Available to Common Stockholders, Basic [Abstract]
Premium paid on repurchase of preferred stock

0

4,127

0

0

Accretion of redeemable convertible preferred units to redemption value

-

-

-

8,663

Redeemable Preferred Stock Dividends

0

12,996

13,925

5,440

Net loss attributable to common stockholders

-514,021

-401,857

-269,841

-230,314

Net loss per share, basic and diluted (usd per share)

-1.55

-4.95

-4.18

-3.79

Weighted average common shares used in net loss per share, basic and diluted (in shares)

330,802

81,114

64,497

60,747

Collaboration revenue
Total revenue

42,803

76,519

146,953

69,109

Collaboration revenue from related party
Total revenue

5,233

45,993

30,021

-

Revenues

-

-

-

32,427

Grant revenue
Total revenue

12,173

12,556

28,851

6,860